Recently, Zhejiang Symer Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Baicheng Pharmaceutical Co., Ltd., obtained marketing approval from the State Drug Administration for marketing of Class 2.2 modified new drug levetiracetam sustained-release granules. This is the first improved new drug approved by Baicheng Pharmaceutical, marking a landmark breakthrough in the field of improved new drug research and development.

Zhitongcaijing · 4d ago
Recently, Zhejiang Symer Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Baicheng Pharmaceutical Co., Ltd., obtained marketing approval from the State Drug Administration for marketing of Class 2.2 modified new drug levetiracetam sustained-release granules. This is the first improved new drug approved by Baicheng Pharmaceutical, marking a landmark breakthrough in the field of improved new drug research and development.